NCT05494528View on ClinicalTrials.gov

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

NAUnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Chronic Hepatitis B Virus Infection
Interventions
DRUG

Ropeginterferon alfa-2b

Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks

DRUG

Entecavir

Entecavir 0.5 mg once per day

Trial Locations (5)

Unknown

NOT_YET_RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

NOT_YET_RECRUITING

China Medical University Hospital, Taichung

RECRUITING

National Taiwan University Hospital, Taipei

NOT_YET_RECRUITING

Taipei Medical University Hospital, Taipei

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

Sponsors

Collaborators (1)

PharmaEssentia
All Listed Sponsors
collaborator

PharmaEssentia

INDUSTRY

lead

National Taiwan University Hospital

OTHER